Cell analysis global market expected to be worth $39,322.3 million by 2025

 

Cell analysis encompasses a wide range of activities that help in understanding and predicting the dynamics that influences cell function, proliferation, their growth and death. This is enabled through analysis of cell signaling mechanisms, elucidation of molecular function, study of cell behavior, and correlating to multiple events with cell morphology, changes in biochemical constituents and cell health. Cell analysis is gaining importance in various fields of applications such as, drug discovery, diagnosis of infectious disease, cancer research, and diagnosis of genetic diseases. Live-cell imaging, single-cell analysis, and high content screening (HCS) are some of the few technological processes gaining more focus in recent times. Single-cell analysis is a rapidly evolving field where individual cells are analyzed for assessment of changing cell behavior and function over time during its natural states or when perturbed by external factors, it is gaining prominence in the cell analysis market because of its extensive application in different research areas.

According to IQ4I analysis, the cell analysis global market expected to reach $39,322.3 million by 2025. The rising incidence of life-threatening infectious diseases, increasing funding and investments in cell-based research from government and corporate, high demand for cell analysis products by end-users, emerging Asia-Pacific market, emerging cell analysis service providers and introduction of automation technologies in cancer research are driving the cell analysis market growth. However, stringent government regulations, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.

The cell analysis market is mainly segmented by techniques, products, applications, end-users and geography. In the cell analysis global market by the technique the molecular approach accounted for the largest share in 2018. Increased awareness about healthcare, increase in government funding, high investment in healthcare infrastructure and increased product launches are driving the adoption of cell analysis technologies. In May 2019, Longas Technologies launched Morphseq long read DNA sequencing technology, which converts short read sequencers into ‘virtual long read’ sequencers, enabling finished-quality genome assemblies with high accuracy, including resolution of difficult-to-assemble genomic regions. The image-based approach is expected to grow at a mid single digit CAGR from 2018 to 2025 due to renewed interest in phenotypic screening, technological advancements in the instruments and launch of various supporting software and increasing adoption of cell-based assay. In the products market, Consumables are holding the largest share in 2018. But the software and services are expected to grow at strong single digit CAGR from 2018 to 2025 due to increased interest on researches and launch of new software. For instance, in October 2018, Mission bio launched Tapestri’s platform which is the only single-cell DNA analysis platform on the list, edging out single-cell platforms focused on transcriptome analysis. The platform plays an important role in Identifying precision cancer treatment targets often involves broad-based next-generation sequencing (NGS).

The cell analysis global market by application is categorized based on processes, type of field and therapeutic area. Among the process of application, cellular process application accounted for the largest revenue in 2018 and the circulating tumor cell market is expected to boom at a high double digit CAGR from 2018 to 2025. Companies are launching new products for the analysis of cancer cells. For instance, in February 2019, Promega Corporation introduced the Maxwell RSC miRNA Plasma and Serum Kit  which offers oncology and translational researchers an easy and automated protocol to purify total circulating RNA, including miRNA, from plasma, serum and enriched exosomes for advanced techniques such as NGS or ddPCR. Based on the field of application, diagnostics sub-segment held the largest revenue in 2018 due to increased prevalence of various diseases and requirement for early detection. Stem cell analysis is expected to grow at a high double digit CAGR from 2018 to 2025, due to increased acceptance of stem cell research and an increase in organ transplantations. Among the different applications based on the therapeutic area, the Cancer research accounted for largest revenue in 2018 due to increase in the incidence of cancer, increased funding initiatives and technological advancements are booming the market.

Among the various end-users of the cell analysis market academic and research institutes generated the largest revenue in 2018, but the Contract Research Organizations are expected to grow at high double digit CAGR from 2018 to 2025 due to increase in the externalization of research activities and also expansion in service capabilities provided by them.

Geographically North America commanded the largest market share in 2018 due to high investments in healthcare infrastructures, availability of government funds improved market growth in this region. However, the Asia-pacific region is expected to grow at high single digit CAGR from 2018 to 2025 due to increased healthcare awareness, improved economic growth, and increasing disposable incomes. Significant launch of new products, agreement, partnership, collaborations, and joint ventures are the industry trends that are playing a major role in market growth. 

Single-cell analysis is one of the major and fastest growing segments in the cell analysis market with double digit growth rate from 2018 to 2025. Single-cell analysis play a major role in the identification of population heterogeneity, identifying minority sub-populations of interest, as well as discovering the unique characteristics of an individual cell that are aiding in drug discovery and development, understanding of disease pathways such as cancer. Single-cell sequencing provides detailed inputs into the composition of single genomes that were not clearly seen in bulk cell sequencing. Companies are receiving research grants for cell-based researches, For instance, In December 2018, Mission Bio raised $30 million in Series B funding for development of its single-cell sequencing.

Major players in cell analysis market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.S.), Merck KGaA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands), GE Healthcare (U.S.) and ThermoFisher Scientific, Inc. (U.S.).